<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2018.86086</article-id><article-id pub-id-type="publisher-id">ACM-26242</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20180600000_40379381.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  miRNA-140作用于肺癌研究进展综述
  Review of the Progress of miRNA-140 in the Study of Lung Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>小玉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>文文</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>真真</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>子舒</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>海霞</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>雁鸿</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>河北医科大学，河北 石家庄</addr-line></aff><aff id="aff3"><addr-line>秦皇岛市第一医院，河北 秦皇岛</addr-line></aff><aff id="aff2"><addr-line>承德医学院研究生院，河北 承德</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>31</day><month>07</month><year>2018</year></pub-date><volume>08</volume><issue>06</issue><fpage>514</fpage><lpage>524</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    miRNA在癌症发生发展中扮演着重要的角色，现有研究表明，miRNAs的异常表达与多种癌症有关，而miRNAs可作为促肿瘤生长因子和肿瘤抑制因子存在。本文从miRNA-140相关信号通路着手，介绍了miRNA-140作为肿瘤抑制因子或致癌基因与肺癌相关性及治疗前景的相关研究,逐步展开miRNA-140在肺癌治疗领域的应用前景。
    miRNA plays an important role in the development of cancer. Existing studies have shown that the abnormal expression of miRNAs is associated with a variety of cancers, and miRNAs can be used as a tumor growth factor and a tumor suppressor factor. From the miRNA-140 related signal pathway, this paper introduces the related research of miRNA-140 as tumor suppressor factor or oncogene and lung cancer, and gradually expands the prospect of miRNA-140 in the field of lung cancer treatment. 
  
 
</p></abstract><kwd-group><kwd>miRNA-140，Lung Cancer，肺癌，信号通路, miRNA-140</kwd><kwd> Lung Cancer</kwd><kwd> Lung Cancer</kwd><kwd> Signal Pathway</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>miRNA-140作用于肺癌研究进展综述<sup> </sup></title><p>王小玉<sup>1</sup>，周文文<sup>2</sup>，王真真<sup>2</sup>，赵子舒<sup>1</sup>，王海霞<sup>3</sup>，杨雁鸿<sup>2*</sup></p><p><sup>1</sup>承德医学院研究生院，河北 承德</p><p><sup>2</sup>秦皇岛市第一医院，河北 秦皇岛</p><p><sup>3</sup>河北医科大学，河北 石家庄</p><disp-formula id="hanspub.26242-formula25"><graphic xlink:href="//html.hanspub.org/file/3-1570619x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2018年6月29日；录用日期：2018年7月26日；发布日期：2018年8月2日</p><disp-formula id="hanspub.26242-formula26"><graphic xlink:href="//html.hanspub.org/file/3-1570619x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>miRNA在癌症发生发展中扮演着重要的角色，现有研究表明，miRNAs的异常表达与多种癌症有关，而miRNAs可作为促肿瘤生长因子和肿瘤抑制因子存在。本文从miRNA-140相关信号通路着手，介绍了miRNA-140作为肿瘤抑制因子或致癌基因与肺癌相关性及治疗前景的相关研究,逐步展开miRNA-140在肺癌治疗领域的应用前景。</p><p>关键词 :miRNA-140，Lung Cancer，肺癌，信号通路</p><disp-formula id="hanspub.26242-formula27"><graphic xlink:href="//html.hanspub.org/file/3-1570619x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-1570619x8_hanspub.png" /> <img src="//html.hanspub.org/file/3-1570619x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>目前肺癌排在世界肿瘤死亡原因的首位，而非小细胞肺癌占肺癌总数的80% [<xref ref-type="bibr" rid="hanspub.26242-ref1">1</xref>] ，因其恶性程度较高，病情发展较为迅速，治疗相对困难。相当一部分肺癌在确诊时已经存在局部或全身的转移，往往预后不良。尽管现阶段对肺癌的治疗研究突飞猛进，但依然没有较好的监测手段去监测其发生发展，总体上肺癌患者的5年生存率仍未有大的突破。随着对miRNA作用机制的深入研究，尤其是miRNA在监测和治疗方面取得的成绩和进展，给我们肺癌监测和治疗领域的发展，提供了新思路。</p><p>miRNA是一段17到25个核长的非编码RNA分子，在信使RNA降解和翻译水平上调节基因表达，并借以调节靶基因活性，miRNA并在大多数类型的癌症及肺癌中都有表达 [<xref ref-type="bibr" rid="hanspub.26242-ref2">2</xref>]。miRNA是公认的作为一类独特的生物转录后的监管机构参与大多数生物过程包括分化、细胞凋亡、增殖、免疫反应等，此外，miRNA在疾病进展中扮演着重要的角色，包括癌症，依赖于其目标基因的生物学功能，可以作为肿瘤抑制因子或致癌因子存在 [<xref ref-type="bibr" rid="hanspub.26242-ref3">3</xref>]。现有研究 [<xref ref-type="bibr" rid="hanspub.26242-ref4">4</xref>] 表明，miRNA-140在人外周循环血浆中的表达有助于监测肺恶性肿瘤的发展变化以及是否发生远处转移。本文对miRNA的起源和发现、miRNA与肺癌相关信号通路和miRNA对肺恶性肿瘤治疗意义前景这几方面进行综述，希望miRNA-140能为肺癌诊断及判断其预后提供一些理论依据。</p></sec><sec id="s4"><title>2. miRNA的发现及其功能</title><p>miRNA最初是1993年Lee等人 [<xref ref-type="bibr" rid="hanspub.26242-ref5">5</xref>] 在对秀丽新小杆线虫发育的研究中发现。细胞核内转录出来的前体RNA经过酶的切割作用后成为成熟miRNA,成熟的miRNA与其他蛋白一起组成RNA-诱导沉默复合体，与mRNA的3’端UTR结合发挥作用 [<xref ref-type="bibr" rid="hanspub.26242-ref6">6</xref>]。若miRNA与靶mRNA完全互补，则该复合体降解mRNA；若两者部分互补，则通过抑制靶mRNA的翻译来沉默特定基因来发挥生物学功能 [<xref ref-type="bibr" rid="hanspub.26242-ref7">7</xref>]。另外，miRNA通过与靶mRNA不完全互补后去除mRNA聚腺苷酸尾，使其被核酸外切酶水解，导致靶mRNA被降解也可能是miRNA调控基因表达的一种方式。</p></sec><sec id="s5"><title>3. miRNA和miRNA-140</title><p>miRNA基因通常是在核内由RNA聚合酶II(polII)转录的，最初产物为大的具有帽子结构(7MGpppG)和多聚腺苷酸尾巴(AAAAA)的pri-miRNA。pri-miRNA在核酸酶Drosha和其辅助因子Pasha的作用下被处理成70个核苷酸组成的pre-miRNA。RNA-GTP和exportin 5蛋白载体将pre-miRNA输送到细胞质中。随后，另一个核酸酶Dicer将其剪切产生约为22个核苷酸长度的miRNA:miRNA双链。这种双链很快被引导进入沉默复合体中，只留其中一条成熟的单链miRNA保留在这一复合体中。成熟的miRNA存在着与靶mRNA的3'端非翻译区(UTR)互补配对的位点，两者识别结合，使翻译无法进行，从而抑制基因表达，见图1。</p><p>最近，越来越多的证据表明，miRNAs的异常表达与多种癌症有关，而miRNAs可作为促肿瘤生长因子和肿瘤抑制因子 [<xref ref-type="bibr" rid="hanspub.26242-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.26242-ref9">9</xref>]。在肺癌中，多种miRNA，如let-7家族，miR-200，miR-486和miR-146a已经被鉴定为肿瘤抑制因子 [<xref ref-type="bibr" rid="hanspub.26242-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.26242-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.26242-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.26242-ref13">13</xref>] ；另一方面，miR-31、miR-212和miR-196a被发现促进肺癌发生 [<xref ref-type="bibr" rid="hanspub.26242-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.26242-ref15">15</xref>] ，见表1。除此之外，miR-140已经引起了广泛关注，因为它参与了各种类型癌症的发生和进展，包括肺癌、胃癌、肝癌、骨肉瘤、结肠癌、乳腺癌和脑胶质瘤 [<xref ref-type="bibr" rid="hanspub.26242-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.26242-ref17">17</xref>]。</p></sec><sec id="s6"><title>4. miRNA相关信号通路</title><sec id="s6_1"><title>4.1. TGF-β信号传导途径</title><p>TGF-β信号途径的异常传导被认为是引起肿瘤发生发展的主要步骤，并且能够导致多种类型肿瘤的发生 [<xref ref-type="bibr" rid="hanspub.26242-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.26242-ref19">19</xref>]。TGF-β的两个受体——TGFBR1和TGFBR2被推测为肿瘤抑制因子，他们的突变能明显导致肿瘤的发生发展。在一些人类癌细胞中，发现了TGFBR1和 TGFBR2的突变。TGFBR2在肿瘤细胞中的高表达，既能通过一些潜在的免疫抑制作用例如刺激血管发生等方式来促进肿瘤演进，还能够通过干扰Smads依赖途径直接影响肿瘤细胞的浸润和转移。</p><p>图1. miRNA的产生及作用机制</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Lung cancer related mRN</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >肺癌相关mRNA</th></tr></thead><tr><td align="center" valign="middle" >肿瘤抑制因子</td><td align="center" valign="middle" >Let-7家族，miR-200，miR-486和miR-146a</td></tr><tr><td align="center" valign="middle" >促肿瘤生长因子</td><td align="center" valign="middle" >miR-31,miR-212和miR-196a</td></tr></tbody></table></table-wrap><p>表1. 部分肺癌相关mRNA</p><p>TGF-β家族成员介导的信号传导需要TGFBR1和TGFBR2的共同参与。TGFBR2只有与TGFBR1 形成复合物才能发挥信号作用，TGFBR1在TGF-β的信号传递中起着限制性作用，并协同TGFBR2在肿瘤发生中的重要作用。TGFBR1突变使TGF-β介导的抑制细胞增殖作用降低或缺失，增加了癌症的易感性。</p><p>随后研究人员确定了TGFBR1和FGF是miR-140的直接靶点，证明miR-140具有肿瘤抑制基因的作用。miR-140和Smad3依赖的信号通路之间存在双向负反馈环。并且miR-140在体内和体外通过抑制p-Smad3的表达进一步降低TGFBR2的表达从而抑制肺癌细胞增殖和转移 [<xref ref-type="bibr" rid="hanspub.26242-ref20">20</xref>]。</p><p>同时最近的研究表明，MMD与肺癌患者的预后密切相关 [<xref ref-type="bibr" rid="hanspub.26242-ref21">21</xref>] ，MMD在成熟的巨噬细胞中优先表达，可能会影响巨噬细胞的活化，促进癌症的发展。相关性统计分析显示MMD mRNA水平与miR-140水平之间存在显著负相关，MMD是miR-140的直接目标。MMD可以与Ras相互作用，增强其在高尔基体的保留和活性，进而导致Erk信号的维持，这是细胞增殖的一个重要信号，MMD是miR-140的重要下游目标。Weina Li等人 [<xref ref-type="bibr" rid="hanspub.26242-ref22">22</xref>] 在研究中证实：1) MMD在肺癌组织中上调表达，与miR-140的表达水平成反比。2) 在MMD mRNA的3’UTR中确定了miR-140的互补序列。3) miR-140的过表达显著降低A549细胞MMD蛋白水平，而抑制miR-140增强MMD表达；4) miR-140过表达降低了荧光素酶反应的的活性，其中包含MMD mRNA的野生型3’UTR，但对含有突变MMD 3’UTR的荧光素酶反应没有影响；5) miR-140对A549细胞增殖的抑制作用被MMD逆转。这些数据有力地表明，miR-140通过下调MMD抑制A549细胞生长。liu等人 [<xref ref-type="bibr" rid="hanspub.26242-ref23">23</xref>] 也证明了MMD的过度表达增加了巨噬细胞中的ERK信号，因此我们有理由怀疑，miR-140/MMD轴通过调节Erk信号来影响TGF-β信号传导通路进而调控肺癌细胞的增殖。</p><p>现阶段研究已证实miR-140抑制了TGF-β和MAPK/ERK信号通路，见图2。</p></sec><sec id="s6_2"><title>4.2. BMP信号传导途径</title><p>BMP\TGF-β信号通路广泛存在于多种生物学过程，在各种恶性肿瘤增殖转移中起重要的调控作用。BMP\TGF-β信号转导包括经典的Smads蛋白依赖的信号通路(包括BMP\TGF-β配体、受体和Smads)及不依赖Smads的非经典通路(如p38、MAPKs)。经典的BMP\TGF-β信号通路首先与相应的BMP或TGF-β受体结合，分别激活Smad1/5/8或Smad2/3，磷酸化的Smad1/5/8或Smad2/3与Smad4蛋白结合形成复合体，该复合体进入细胞核以直接或间接方式活化成肿瘤特异性转录因子，继而促进或抑制肿瘤的增殖与转移。</p><p>Dumont等人 [<xref ref-type="bibr" rid="hanspub.26242-ref24">24</xref>] 研究乳腺癌细胞发现，TGF-βⅡ型受体(dnTpRⅡ)的表达有效地阻断了TGF-β信号和BMP信号，当使用BMP-2刺激60 min后，观察到对照组即不表达dnT3RⅡ的细胞中磷酸化的Smad1激增，dnT3REⅡ的表达削弱了BMP-2介导的Smadl的磷酸化；荧光素酶是由BMP-2激活的，使用BMP-2刺激细胞24 h后，发现对照组细胞荧光素酶活性被强烈诱导，而表达TBRⅡ的细胞荧光素酶活性小/无，表明表达TBRⅡ的细胞也减弱了BMP-2介导的Smad依赖的转录反应。研究还发现,阻断BMP信号会使其信号通路介导的抗增殖效应降低。该研究从侧面证实了BMP-2具有抑制乳腺癌细胞增殖的作用。</p><p>现有研究表明，miR-140可以直接作用于BMP-2受体影响TGF-β信号和BMP信号的传导，调节Smad依赖的转录反应，抑制肿瘤的增殖与转移 [<xref ref-type="bibr" rid="hanspub.26242-ref25">25</xref>] ，见图3。</p></sec><sec id="s6_3"><title>4.3. 胰岛素样生长因子1受体途径</title><p>胰岛素样生长因子1受体(insulin-like growth factor-1 receptor, IGF-1R)是一跨膜酪氨酸激酶受体。胰岛素样生长因子(IGF)和胰岛素样生长因子受体家族(IGF-1R、IGF-2R)在细胞信号转导过程中起重要作用，IGF-1R下游信号通路主要有丝裂原激活蛋白激酶(MAPK)通路和磷脂腺肌醇3激酶(PI3K/Akt)通路，参与调节细胞生长、分化、凋亡、转化和其它重要的生理过程，并在许多肿瘤细胞系中过表达。</p><p>图2. mRNA-140作用于TGF-β信号传导途径</p><p>图3. mRNA-140作用于BMP信号传导途径</p><p>许多研究表明，IGF及其受体IGF1R，能通过改变肿瘤细胞周期、细胞凋亡以及与周围环境的等方式，在调控肺癌等恶性肿瘤持续生长中起着重要的作用。在肺癌各病理类型肿瘤细胞中，高水平表达的IGF可通过自分泌或旁分泌的方式，使体外细胞呈现恶性表型、形成体内瘤体及加强肿瘤细胞抗凋亡能力 [<xref ref-type="bibr" rid="hanspub.26242-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.26242-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.26242-ref28">28</xref>]。</p><p>Yunfeng Yuan [<xref ref-type="bibr" rid="hanspub.26242-ref29">29</xref>] 等人利用靶区扫描分析技术发现，miR-140的互补序列在IGF1R的3'UTR中被识别并与之作用，从而下调其的表达。miR-140在肺癌组织和细胞系中明显下调，IGF1R在肺癌组织中受正反馈影响并与miR-140的表达水平成反比。这些数据有力地表明，miR-140通过下调IGF1R抑制了肺癌的生长和转移，频繁下调的miR-140会导致IGF1R的表达增加，进而促进恶性肿瘤的发生和进展，见图4。</p></sec></sec><sec id="s7"><title>5. miRNA的在各类恶性肿瘤的研究</title><sec id="s7_1"><title>5.1. miRNA在乳腺癌的研究</title><p>关于miR-140与乳腺癌之间的研究，有研究分析正常乳腺组织和乳腺癌组织，发现miR-140具有抑癌功能 [<xref ref-type="bibr" rid="hanspub.26242-ref30">30</xref>] [<xref ref-type="bibr" rid="hanspub.26242-ref31">31</xref>]。2012年，Zhang等 [<xref ref-type="bibr" rid="hanspub.26242-ref32">32</xref>] 发现，miR-140靶向调控转录因子SOX2，影响乳腺肿瘤细胞的生长。我们在前期研究中发现，miR-140在低转移的乳腺癌细胞中的表达量要比在高转移的乳腺癌细胞中的表达量高近5倍。于影 [<xref ref-type="bibr" rid="hanspub.26242-ref33">33</xref>] 的研究发现，Nrf2可能是miR-140又一个新的靶基因，细胞增殖实验表明，miR-140可能是通过下调Nrf2的表达来抑制乳腺癌细胞的增殖，并且增强细胞对氧化应激的敏感性。同时揭示了一个新的抑制Nrf2/ARE信号通路的小分子，为逆转肿瘤耐药提供了一个理论基础。同时miR-140可能成为抗癌化学疗法的新靶点，并且为癌症的治疗提供一个新的思路。</p></sec><sec id="s7_2"><title>5.2. miRNA在脑胶质瘤的研究</title><p>脑胶质瘤是中枢神经系统肿瘤中最常见的恶性肿瘤，占全部颅内肿瘤40%~50%，具有高发病率、高复发率、高进展性、高病死率和低治愈率的特点 [<xref ref-type="bibr" rid="hanspub.26242-ref34">34</xref>] [<xref ref-type="bibr" rid="hanspub.26242-ref35">35</xref>] ，随着科学技术以及生物信息技术的不断发展，现有证据表明，miRNA 的异常表达与肿瘤密切相关，广泛地参与了肿瘤的发生和发展进程，其中大约50%的miRNA都位于肿瘤相关基因组区域或染色体脆性位点 [<xref ref-type="bibr" rid="hanspub.26242-ref36">36</xref>] ，为了研究miR-140在人脑胶质瘤组织细胞中的表达特性，吴淳等人 [<xref ref-type="bibr" rid="hanspub.26242-ref37">37</xref>] 采用实时定量PCR技术检测miR-140在非瘤脑组织、不同级别人脑胶</p><p>图4. mRNA-140作用于IGF-1R信号传导途径</p><p>质瘤组织以及SHG44、U87、U251和U373等人脑胶质瘤细胞株中的表达情况，结果表明过表达miR-140可以抑制胶质瘤细胞株U251和U87MG的增殖，阻滞细胞周期，促使其细胞凋亡，并可有效抑制其侵袭力。</p></sec><sec id="s7_3"><title>5.3. miRNA在肝癌的研究</title><p>肝细胞癌(HCC)占主要肝癌的大部分，最近的研究进展显示，己有许多研究报道发现在肝癌中存在miRNA的异常表达。杨浩等人 [<xref ref-type="bibr" rid="hanspub.26242-ref38">38</xref>] 的研究中发现miR-140在肝癌组织和细胞中均呈低表达，且其低表达与与肝癌病人的临床病理特征和预后密切相关，低表达miR-140的肝癌患者预示着不良的预后。进而阐明了miR-140是通过靶向调节TGFBR1和FGF并进而抑制TGFβ和FGF/ERK信号通路来发挥抑制肝癌细胞侵袭转移和生长增殖的作用，并证实了miR-140具有抑制肝癌细胞侵袭转移和生长增殖的作用。研究结果提示miR-140可作为肝癌新的预后标志物及潜在治疗靶点。</p></sec><sec id="s7_4"><title>5.4. miRNA在胃癌的研究</title><p>胃癌细胞的增殖侵袭等细胞活动是一个极其复杂的过程，研究表明有多种基因、酶类及细胞因子等参与调控促进或抑制胃癌的细胞活动，但至今胃癌细胞发生发展的确切分子机制仍未充分阐明 [<xref ref-type="bibr" rid="hanspub.26242-ref39">39</xref>] ，王显艳 [<xref ref-type="bibr" rid="hanspub.26242-ref40">40</xref>] 等学者研究发现总体上miR-140在胃癌组织中表达水平低于正常胃组织，并且与肿瘤大小、侵袭度、淋巴转移分期相关，胃癌肿瘤生长越大，侵袭度、淋巴转移分期越高，miR-140相对表达水平越低，同时miR-140可通过负调控 HDAC4 发挥抑制胃癌细胞增殖、侵袭并促进凋亡的作用。提示miR-140可能作为抑癌因子在人胃癌侵袭和转移等细胞功能中发挥作用。</p></sec><sec id="s7_5"><title>5.5. miRNA在骨肉瘤的研究</title><p>为了研究miR-140在Saos-2细胞中的作用及机制，刘玲丽等人 [<xref ref-type="bibr" rid="hanspub.26242-ref41">41</xref>] 选取IGF1R、MMP2、MMP7、MMP9等肿瘤相关因子进行mRNA及蛋白水平的检测，结果显示上调miR-140-5p表达后，与肿瘤预后关系密切的IGF1R表达下调最明显，与肿瘤细胞迁移侵袭相关的MMP9也表现为表达下调，与细胞凋亡相关的caspase-3表现为表达上调。</p><p>目前研究可知，IGF2/IGF1R信号通路可能是导致骨肉瘤高恶性行为的关键一环，包括Ewing's肉瘤是最早发现该通路调控失衡是导致恶性肿瘤的主要因素，IGF1R几乎在大部分肿瘤细胞中都存在过量表达 [<xref ref-type="bibr" rid="hanspub.26242-ref30">30</xref>] [<xref ref-type="bibr" rid="hanspub.26242-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.26242-ref34">34</xref>]。最新研究报道在非小细胞肺癌(NSCLC)中，已证实IGF 1R为miR-140的靶基因，miR-140通过下调IGF1R抑制肿瘤细胞的增殖、迁移和侵袭 [<xref ref-type="bibr" rid="hanspub.26242-ref34">34</xref>]。IGFIR作为单克隆抗体，已应用于肿瘤治疗的临床试验。在本实验中，上调Saos-2细胞miR-140表达后，IGF1R的表达下降，表明上调miR-140后，Saos-2细胞的增殖和迁移能力均受到明显抑制，miR-140在骨肉瘤细胞中表现为抑癌基因，miR-140在骨肉瘤中的具体作用机制还有待进一步的研究。</p></sec><sec id="s7_6"><title>5.6. miRNA在结肠癌的研究</title><p>Song等 [<xref ref-type="bibr" rid="hanspub.26242-ref42">42</xref>] 研究显示，miR-140在人结直肠癌组织中的表达显著低于其对应的正常肠黏膜，miR-140瞬时转染可导致结肠癌细胞在G1和G2期阻滞，并抑制其增殖，表明miR-140与人结直肠癌的发生有密切关系。Smad3是TGF-β信号通路中的主要转录因子。Pais等 [<xref ref-type="bibr" rid="hanspub.26242-ref43">43</xref>] 应用Northern blot和荧光素酶报告系统证明，Smad3是miR-140的直接靶点。赵文月等人 [<xref ref-type="bibr" rid="hanspub.26242-ref44">44</xref>] 的研究显示，转染miR-140可下调RKO细胞中Smad3蛋白的表达，但mRNA水平无显著变化，提示miR-140是在翻译水平调控Smad3的表达，与Pais等报道一致。本研究中，分别转染miR-140或Smad3 siRNA的细胞，迁移和侵袭能力均明显下降。应用特异性抑制物下调miR-140后，Smad3表达增高，细胞的迁移和侵袭能力也显著增强。而miR-140抑制剂和Smad3 siRNA同时转染细胞时，Smad3蛋白表达无明显变化，细胞的迁移和侵袭能力也无显著改变。</p><p>综上所述，miR-140可能通过下调肿瘤转移相关因子Smad3而抑制结肠癌细胞的迁移和侵袭能力，miR-140可能作为肿瘤转移诊断及治疗的潜在候选靶点。</p></sec><sec id="s7_7"><title>5.7. miRNA在肺癌的研究</title><p>在肺癌中，非小细胞肺癌占据肺癌总数的80%，而其中肺腺癌占据非小细胞肺癌总数的50%以上，包括EGFR在内的KRAS，HER2，PIK3CA，BRAF，MET基因突变和ALK，ROS1和RET基因重排也十分常见。鳞状细胞癌在非小细胞肺癌中排名第二，大约占20%~30%的病例。在鳞状细胞癌中，EGFR基因突变非常罕见，只有成纤维细胞生长因子受体-1(FGFR1)的基因扩增，盘状结构域受体2 (DDR2)基因突变和PI3KCA基因的扩增和突变比较常见。</p><p>为确定在肺癌组织中miRNA表达的调控和预测价值，以确定miRNAs的表达是否可以用于识别NSCLC和控制病例，Ling Hu [<xref ref-type="bibr" rid="hanspub.26242-ref45">45</xref>] 等人研究了19个相关文献报道，在删除3个重复的数据和11个无效数据之后进行了荟萃分析，提出miR-140能显著降低非小细胞肺癌中MMD蛋白水平，从而通过调节erk1/2信号传导抑制细胞增殖，提出miR-140跟其它13种miRNA一起作为组合，具有更准确的预测价值，以更高的灵敏度，更高的特化率和统计意义的途径来区分癌症病例。</p><p>对于肺癌的传统方法包括手术切除，放化疗在内，都是通过各种方式减少机体肿瘤细胞的数量，从而达到治疗肺癌的目的，但是很容易一段时间后肺癌又会复发转移，这与其基因易感这种发病机制密不可分。技术进步提高了肺癌的诊断和治疗，但死亡率仍然很高。肺癌在早期可治愈的阶段几乎未被发现，而且缺乏有效的抗肿瘤药物，除了一些靶向治疗外，几乎没有快速有效针对的方法。</p><p>鉴于肺腺癌占据非小细胞肺癌超过半数比例、可研究的信号通路较多，我们关注的是，miR-140与一些常规的化疗药物或靶向药物如(顺铂、BMP型受体拮抗剂或吉非替尼等)联合治疗肺腺癌是否能提高其预防恶性肿瘤进展的功效。EGFR在许多肿瘤中被过度表达，包括肺癌，在所有病例中，基因突变约占10%~35% [<xref ref-type="bibr" rid="hanspub.26242-ref46">46</xref>]。它的构成激活导致恶性肿瘤的进展，并与存活率降低、淋巴结转移和化疗敏感性差异 [<xref ref-type="bibr" rid="hanspub.26242-ref47">47</xref>] 有关。与EGFR通路一样，骨形态发生蛋白(BMP)信号级联反应在肺癌中被激活。证据表明BMP型受体拮抗剂可预防疾病进展 [<xref ref-type="bibr" rid="hanspub.26242-ref48">48</xref>] [<xref ref-type="bibr" rid="hanspub.26242-ref49">49</xref>]。BMP是属于转化生长因子β (TGF-β)超家族的生长因子，并将其跨膜丝氨酸/苏氨酸激酶受体结合在细胞表面(I型和II型受体)上。ALK2受体是BMP I型受体，尽管ALK2基因突变不如EGFR中的突变，但它们占所有肺癌病例的约3%~7%。VALENTINA FLAMINI [<xref ref-type="bibr" rid="hanspub.26242-ref3">3</xref>] 等实验研究中包含的药物是吉非替尼，ALK2抑制剂和顺铂，并且采用肺A549细胞进行实验。所有这些已经被批准并且目前用于肺癌患者。EGFR和ALK2抑制剂在肺癌侵袭中的抑制作用是众所周知的，但是我们在意的是它们是否可以通过加入miR-140类似物来增强活性。实验已经证实，miR-140与顺铂联合降低了A549细胞的增殖，这种作用在miR-140替代独立治疗中没有观察到。在A549细胞中，miR-140和吉非替尼的组合也降低了体外癌细胞的迁移能力，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> An overview of VALENTINA FLAMINI Experimental Researc</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >药物</th><th align="center" valign="middle" >作用靶点</th><th align="center" valign="middle" >加入miR-140后A549增殖情况</th></tr></thead><tr><td align="center" valign="middle" >吉非替尼</td><td align="center" valign="middle" >EGFR</td><td align="center" valign="middle" >抑制</td></tr><tr><td align="center" valign="middle" >克唑替尼</td><td align="center" valign="middle" >ALK-2/BMP</td><td align="center" valign="middle" >抑制</td></tr><tr><td align="center" valign="middle" >顺铂</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >抑制</td></tr><tr><td align="center" valign="middle" >miR-140单药</td><td align="center" valign="middle" >TGF-β/BMP/IGF-1</td><td align="center" valign="middle" >变化不明显</td></tr></tbody></table></table-wrap><p>表2. VALENTINA FLAMINI实验研究总览</p><p>这个研究结果带给我们临床诊治的新思路，然而现阶段所有的实验都是在离体细胞上进行的，miR-140在活体内及作用在肺鳞癌细胞的效果仍属未知，但是我们有理由相信miR-140有一个美好的前景，不论是临床应用还是与其他癌种的相关性都值得进一步探讨。</p></sec></sec><sec id="s8"><title>文章引用</title><p>王小玉,周文文,王真真,赵子舒,王海霞,杨雁鸿. miRNA-140作用于肺癌研究进展综述 Review of the Progress of miRNA-140 in the Study of Lung Cancer[J]. 临床医学进展, 2018, 08(06): 514-524. https://doi.org/10.12677/ACM.2018.86086</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.26242-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">李冰. 非小细胞肺癌的综合诊治策略——NCCN肿瘤学临床实践指南(2006第二版)评析[J]. 医学与哲学, 2007, 28(14): 66-67.</mixed-citation></ref><ref id="hanspub.26242-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Gozuacik, D., Akkoc, Y., Ozturk, D.G., et al. (2017) Autophagy-Regulating microRNAs and Cancer. Frontiers in Oncology, 7, 65. &lt;br&gt;https://doi.org/10.3389/fonc.2017.00065</mixed-citation></ref><ref id="hanspub.26242-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Valentina, F.L., Ami, N.I., Jiang, W.G. and Cui, Y. (2017) Therapeutic Role of miR-140 for the Treatment of Non-small Cell Lung Cancer. Anticancer Research, 37, 4319-4327.</mixed-citation></ref><ref id="hanspub.26242-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Jeong, H.C. (2014) Clinical Aspect of MicroRNA in Lung Cancer. Tuberculosis &amp; Respiratory Diseases, 77, 60-64.  
&lt;br&gt;https://doi.org/10.4046/trd.2014.77.2.60</mixed-citation></ref><ref id="hanspub.26242-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Lee, R.C., Feinbaum, R.L., Ambros, V., et al. (1993) The C. elegans Heterochronicgene lin-4 Encodes Small RNAs with Antisense Complementarity to lin-14. Cell, 75, 843-854. &lt;br&gt;https://doi.org/10.1016/0092-8674(93)90529-Y</mixed-citation></ref><ref id="hanspub.26242-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Scott, G.K., Goga, A., Bhaumik, D., et al. (2006) Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-l25a or miR-125b. The Journal of Biological Chemistry, 282, 1479-1486.  
&lt;br&gt;https://doi.org/10.1074/jbc.M609383200</mixed-citation></ref><ref id="hanspub.26242-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Finnegan, E.J. and Matzke, M.A. (2003) The Small RNA World. Journal of Cell Science, 116, 4689-4693.</mixed-citation></ref><ref id="hanspub.26242-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Garzon, R. and Croce, C.M. (2008) miRNAs in Normal and Malignant Hematopoiesis. Current Opinion in Hematology, 15, 352-358. &lt;br&gt;https://doi.org/10.1097/MOH.0b013e328303e15d</mixed-citation></ref><ref id="hanspub.26242-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ventura, A. and Jacks, T. (2009) miRNAs and Cancer: Short RNAs Go a Long Way. Cell, 136, 586-591.</mixed-citation></ref><ref id="hanspub.26242-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Kumar, M.S., Erkeland, S.J., Pester, R.E., Chen, C.Y., Ebert, M.S., et al. (2008) Suppression of Non-Small Cell Lung Tumor Development by the Let-7 miRNA Family. Proceedings of the National Academy of Sciences of the United States of America, 105, 3903-3908. &lt;br&gt;https://doi.org/10.1073/pnas.0712321105</mixed-citation></ref><ref id="hanspub.26242-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Usufović, E., Rijavec, M., Keser, D., Korošec, P., Sodja, E., et al. (2012) let-7b and miR-126 Are Down-Regulated in Tumor Tissue and Correlate with Microvessel Density and Survival Outcomes in non-Small-Cell Lung Cancer. PLOS ONE, 7, e45577. &lt;br&gt;https://doi.org/10.1371/journal.pone.0045577</mixed-citation></ref><ref id="hanspub.26242-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Schliekelman, M.J., Gibbons, D.L., Faca, V.M., Creighton, C.J., Rizvi, Z.H., et al. (2011) Targets of the Tumor Suppressor miR-200 in Regulation of the Epithelial-Mesenchymal Transition in Cancer. Cancer Research, 71, 7670-7682.  
&lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-11-0964</mixed-citation></ref><ref id="hanspub.26242-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J., Tian, X., Han, R., Zhang, X., Wang, X., et al. (2013) Downregulation of miR-486-5p Contributes to Tumor Progression and Metastasis by Targeting Protumorigenic ARHGAP5 in Lung Cancer. Oncogene. [Epub ahead of print]. PubMed: 23474761.</mixed-citation></ref><ref id="hanspub.26242-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Chen, G., Umelo, I.A., Lv, S., Teugels, E., Fostier, K., et al. (2013) miR-146a Inhibits Cell Growth, Cell Migration and Induces Apoptosis in Non-Small Cell Lung Cancer Cells. PLOS ONE, 8, e60317.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0060317</mixed-citation></ref><ref id="hanspub.26242-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Liu, X., Sempere, L.F., Ouyang, H., Memoli, V.A., Andrew, A.S., et al. (2010) miRNA-31 Functions as an Oncogenic miRNA in Mouse and Human Lung Cancer Cells by Repressing Specific Tumor Suppressors. Journal of Clinical Investigation, 120, 1298-1309. &lt;br&gt;https://doi.org/10.1172/JCI39566</mixed-citation></ref><ref id="hanspub.26242-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Li, Y., Zhang, D., Chen, C., Ruan, Z., Li, Y., et al. (2012) miRNA-212 Displays Tumor-Promoting Properties in Non-Small Cell Lung Cancer Cells and Targets the Hedgehog Pathway Receptor PTCH1. Molecular Biology of the Cell, 23, 1423-1434. &lt;br&gt;https://doi.org/10.1091/mbc.e11-09-0777</mixed-citation></ref><ref id="hanspub.26242-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Liu, X.H., Lu, K.H., Wang, K.M., Sun, M., Zhang, E.B., et al. (2012) miRNA-196a Promotes Non-Small Cell Lung Cancer Cell Proliferation and Invasion through Targeting HOXA5. BMC Cancer, 12, 348.  
&lt;br&gt;https://doi.org/10.1186/1471-2407-12-348</mixed-citation></ref><ref id="hanspub.26242-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, H.T., Chen, X.F., Wang, M.H., et al. (2004) Defective Expression of Transforming Growth Factor Beta Receptor Type II Is Associated with Cp G Methylated Promoter in Primary Non-Small Cell Lung Cancer. Clinical Cancer Research, 10, 2359-2367.</mixed-citation></ref><ref id="hanspub.26242-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Milani, L., Lundmark, A., Nordlund, J., et al. (2009) Allele-Specific Gene Expression Patterns in Primary Leukemic Cells Reveal Regulation of Gene Expression by Cp G Site Methylation. Genome Research, 19, 1-11.</mixed-citation></ref><ref id="hanspub.26242-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">张延霞. miR-21/miR-140/miR-206在肺腺癌发病中的作用研究[D]: [硕士学位论文]. 烟台: 滨州医学院, 2013.</mixed-citation></ref><ref id="hanspub.26242-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Chen, H.Y., Yu, S.L., Chen, C.H., Chang, G.C., Chen, C.Y., Yuan, A., et al. (2007) A Five-Gene Signature and Clinical Outcome in Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 356, 11-20.  
&lt;br&gt;https://doi.org/10.1056/NEJMoa060096</mixed-citation></ref><ref id="hanspub.26242-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Li, W. and He, F. (2014) Monocyte to Macrophage Differentiation-Associated (MMD) Targeted by miR-140 Regulates Tumor Growth in Non-Small Cell Lung Cancer. Biochemical and Biophysical Research Communications, 450, 844-850. &lt;br&gt;https://doi.org/10.1016/j.bbrc.2014.06.075</mixed-citation></ref><ref id="hanspub.26242-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Q., Zheng, J., Yin, D.D., Xiang, J., He, F., Wang, Y.C., et al. (2012) Monocyte to Macrophage Differentiation-Associated (MMD) Positively Regulates ERK and Akt Activation and TNF-a and No Production in Macrophages. Molecular Biology Reports, 39, 5643-5650. &lt;br&gt;https://doi.org/10.1007/s11033-011-1370-5</mixed-citation></ref><ref id="hanspub.26242-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Reddi, A.H. (1998) Role of Morphogenetic Proteins in Skeletal Tissue Engineering and Regeneration.</mixed-citation></ref><ref id="hanspub.26242-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Yang, R., Zhang, D., Yu, K., et al. (2018) Detection of miR-22, miR-140 and Bone Morphogenetic Proteins (BMP)-2 Expression Levels in Synovial Fluid of Osteoarthritis Patients before and after Arthroscopic Debridement. Medical Science Monitor International Medical Journal of Experimental &amp; Clinical Research, 24, 863-868.  
&lt;br&gt;https://doi.org/10.12659/MSM.908110</mixed-citation></ref><ref id="hanspub.26242-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Depinho, R. (2000) The Age of Cancer. Nature, 408, 248-254. &lt;br&gt;https://doi.org/10.1038/35041694</mixed-citation></ref><ref id="hanspub.26242-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Megyesi, K., Kahn, C.R., Roth, J., et al. (1975) The NSILA-s Receptor in Liver Plasma Membranes. Characterization and Comparison with the Insulin Receptor. The Journal of Biological Chemistry, 250, 8990-8996.</mixed-citation></ref><ref id="hanspub.26242-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Bhaumick, B., Bala, R.M. And Hollenberg, M.D. (1981) Somatomedin Receptor of Human Placenta: Lubilization, Photolabeling, Partial Purification and Comparison with Insulin Receptor. Proceedings of the National Academy of Sciences of the United States, 78, 4279-4283. &lt;br&gt;https://doi.org/10.1073/pnas.78.7.4279</mixed-citation></ref><ref id="hanspub.26242-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Yuan, Y., Shen, Y., Xue, L., et al. (2013) miR-140 Suppresses Tumor Growth and Metastasis of Nonsmall Cell Lung Cancer by Targeting Insulin-Like Growth Factor 1 Receptor. PLoS ONE, 8, e73604.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0073604</mixed-citation></ref><ref id="hanspub.26242-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Lorio, M.V., Ferracin, M., Liu, C.G., et al. (2005) MicroRNA Gene Expression Deregulation in Human Breast Cancer. Cancer Research, 65, 7065-7070. &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-05-1783</mixed-citation></ref><ref id="hanspub.26242-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Yan, I.X., Huang, X.F., Shao, Q., et al. (2008) MieroRNA miR-21 Overexpression in Human Breast Cancer Is Associated with Advanced Clinical Stage, Lymph Node Metastasis and Patient Poor Prognosis. RNA, 14, 2348-2360.  
&lt;br&gt;https://doi.org/10.1261/rna.1034808</mixed-citation></ref><ref id="hanspub.26242-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y., Eades, G., Yao, Y., et al. (2012) Estrogen Receptor Alpha Signaling Regulates Breast Tumor Initiating Ceils by Downregulating miR-140 Which Targets the Transcription Factor SOX2. The Journal of Biological Chemistry, 287, 41514-41522. &lt;br&gt;https://doi.org/10.1074/jbc.M112.404871</mixed-citation></ref><ref id="hanspub.26242-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">于影, 李豪杰, 温传俊. MicroRNA-140在乳腺癌细胞中对Nrf2及其下游抗氧化基因的表达调控[J]. 国际免疫学杂志, 2013, 36(4): 303-309.</mixed-citation></ref><ref id="hanspub.26242-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Jin, T., Ding, Q., Huang, H., Xu, D., Jiang, Y., Zhou, B., et al. (2012) PAQR10 and PAQR11 Mediate Ras Signaling in the Golgi Apparatus. Cell Research, 22, 661-676. &lt;br&gt;https://doi.org/10.1038/cr.2011.161</mixed-citation></ref><ref id="hanspub.26242-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Sathornsumetee, S., Rich, J.N. and Reardon, D.A. (2007) Diagnosis and Treatment of High-Grade Astrocytoma. Neurologic Clinics, 25, 1111-1139. &lt;br&gt;https://doi.org/10.1016/j.ncl.2007.07.004</mixed-citation></ref><ref id="hanspub.26242-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Louis, D.N., Ohgaki, H., Wiestler, O.D., et al. (2007) The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathologica, 114, 97-109. &lt;br&gt;https://doi.org/10.1007/s00401-007-0243-4</mixed-citation></ref><ref id="hanspub.26242-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">吴淳. miR-140抑制胶质瘤细胞株U251、U87增殖和侵袭性的实验研究[D]: [硕士学位论文]. 苏州: 苏州大学, 2015: 1-55.</mixed-citation></ref><ref id="hanspub.26242-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">杨浩. miR-140-5p通过靶向调节TGFBR1和FGF9抑制肝细胞癌增殖和侵袭转移[D]: [博士学位论文]. 长沙: 中南大学, 2013.</mixed-citation></ref><ref id="hanspub.26242-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">韦尉元, 曹稳珑, 张笑石, 等. miRNA-1284在胃癌中的表达及其作用机制研究[J]. 中国病理生理杂志, 2015, 31(3): 440-446.</mixed-citation></ref><ref id="hanspub.26242-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">王显艳, 高峰, 赵春明, 孙玉荣, 温秋婷, 于秀文, 张晓杰. miR-140在人胃癌组织中的表达及对SGC-7901胃癌细胞功能的影响[J]. 中国病理生理杂志, 2016, 32(4): 651-657.</mixed-citation></ref><ref id="hanspub.26242-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">刘玲丽. miR-140在骨肉瘤中表达及功能的初步研究[D]: [硕士学位论文]. 沈阳: 中国医科大学, 2015.</mixed-citation></ref><ref id="hanspub.26242-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Song, B., Wang, Y., Xi, Y., et al. (2009) Mechanism of Chemoresistance Mediated by miR-140 in Human Osteosarcoma and Colon Cancer Cell. Oncogene, 28, 4065-4074. &lt;br&gt;https://doi.org/10.1038/onc.2009.274</mixed-citation></ref><ref id="hanspub.26242-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Pais, H., Nicolas, F.E., Soond, S.M., et al. (2010) Analyzing mRNA Expression Identifies Smad3 as a microRNA-140 Target Regulated Only at Protein Level. RNA, 16, 489-494. &lt;br&gt;https://doi.org/10.1261/rna.1701210</mixed-citation></ref><ref id="hanspub.26242-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">赵文月, 邹佳芮, 王波, 范盼红, 毛俊, 李嘉芝, 刘涵, 肖晶, 马威. miR-140通过下调Smad3表达抑制结肠癌细胞迁移和侵袭能力[J]. 中华肿瘤杂志, 2014, 36(10): 739-745.</mixed-citation></ref><ref id="hanspub.26242-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Ling, H., Ai, J., Hui, L., et al. (2016) Integrative miRNA and Gene Profiling Data Analysis Reveals Novel Biomarkers and Mechanisms for Lung Cancer. Oncotarget, 7, 8441-8454.</mixed-citation></ref><ref id="hanspub.26242-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">&lt;br&gt;https://www.mycancergenome.org/content/disease/lung-cancer/</mixed-citation></ref><ref id="hanspub.26242-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Bethune, G., Bethune, D., Ridgway, N. and Xu, Z. (2011) Epidermal Growth Factor Receptor (EGFR) in Lung Cancer: An Overview and Update. Journal of Thoracic Disease, 2, 48-51.</mixed-citation></ref><ref id="hanspub.26242-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Langenfeld, E., Hong, C.C., Lanke, G. and Langenfeld, J. (2013) Bone Morphogenetic Protein Type I Receptor Antagonists Decrease Growth and Induce Cell Death of Lung Cancer Cell Lines. PLoS ONE, 8, e61256.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0061256</mixed-citation></ref><ref id="hanspub.26242-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Hao, J., Lee, R., Chang, A., Fan, J., Labib, C., Parsa, C., Orlando, R., Andresen, B. and Huang, Y. (2014) DMH1, a Small Molecule Inhibitor of BMP Type I Receptors, Suppresses Growth and Invasion of Lung Cancer. PLoS ONE, 9, e90748. &lt;br&gt;https://doi.org/10.1371/journal.pone.0090748</mixed-citation></ref></ref-list></back></article>